Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 5 versus DYANAVEL XR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 5 versus DYANAVEL XR 10.
ADDERALL 5 vs DYANAVEL XR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
None Documented
None Documented
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary pH >7.
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Category C
Category C
CNS Stimulant
CNS Stimulant